Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2025)

Enanta Pharmaceuticals' Current Leases history spans 9 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Current Leases rose 226.74% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 226.74%, while the annual FY2025 figure was $3.1 million, 106.43% up from the prior year.
  • Current Leases reached $3.3 million in Q4 2025 per ENTA's latest filing, up from $3.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.4 million in Q2 2023 to a low of $1.0 million in Q4 2024.
  • Average Current Leases over 5 years is $3.5 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for Current Leases: tumbled 79.74% in 2024, then surged 226.74% in 2025.
  • A 5-year view of Current Leases shows it stood at $3.5 million in 2021, then increased by 0.49% to $3.5 million in 2022, then skyrocketed by 42.46% to $5.0 million in 2023, then crashed by 79.74% to $1.0 million in 2024, then soared by 226.74% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Current Leases are $3.3 million (Q4 2025), $3.1 million (Q3 2025), and $2.4 million (Q2 2025).